Oxurion

Foundation date

30/05/2006

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Oxurion is dedicated to developing and commercializing new pharmacologic ophthalmic treatments that address important unmet clinical needs. By meeting this goal Oxurion intends to help patients around the world with a new or better treatment for their condition.

Upcoming events

Latest news

  • argenx announces VYVGART (efgartigimod alfa) authorized for sale by Health Canada for generalized myasthenia gravis

    Thursday September 21st 2023

  • Galapagos appoints Simon Sturge to its Board of Directors

    Tuesday September 19th 2023

  • 13th Investment for HERAN Partners: Broken String Biosciences (UK)

    Tuesday September 19th 2023